First Public Meeting of FDA Nanotechnology Task Force Raises Many Questions, Few Answers
This month, the FDA convened a diverse group of those using and investing in nanoscale technologies for a public meeting to discuss whether the agency should increase its regulations of products using nanotechnology. There was a mixed response from the audience about how involved the FDA should be in regulating nanotechnology products, with some believing the FDA is doing enough, while others felt some testing, like for nano-cosmetics, is overdue. There was also no consensus on how to define a ‚Äúnanoparticle,‚ÄĚ and many believed a definition is not even necessary. This was the first public meeting of the FDA Nanotechnology Task Force, which was officially formed in August of this year.